ADPM06, a lead candidate azadipyrromethene, is a novel nonporphyrin photodynamic therapeutic (PDT) agent. ADPM06 exhibits IC₅₀ values in the micro-molar range in human tumor cells and induces apoptosis^[1].

The efficacy of ADPM01 is completely ablated at a 1% oxygen level in Hela and MRC5 cell lines. ADPM06 displays only a partial reduction in light-induced activity in hypoxic as compared to normoxic conditions^[1].
ADPM06-PDT induces ER stress and unfolded protein response^[2].
ADPM06-PDT induces apoptosis and involves caspase enzymatic activity^[2].
Following ADPM06-PDT, a rapid processing of XBP1 mRNA occurs resulting in the removal of an intron from the mRNA in a spliceosome-independent manner, a post-transcriptional modification catalyzed by the action of activated inositol-requiring protein 1 (IRE1)^[2].
ADPM06-PDT-induced apoptosis involves the generation of ROS^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

ADPM06-PDT has revealed an initiation of apoptosis in vivo, as well as induction of an ER stress response^[2].
ADPM06-PDT is well tolerated in vivo and elicits impressive complete response rates in various models of cancer when a short drug-light interval is applied^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

715.19

C₃₄H₂₄BBr₂F₂N₃O₂

490035-90-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. W M Gallagher, et al. A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia. Br J Cancer. 2005 May 9; 92(9): 1702-1710.

  [2]. Aisling E O’Connor, et al. Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo. Int J Cancer. 2012 Feb 1;130(3):705-15.